Beam Therapeutics Inc
Beam Therapeutics Inc (BEAM) is a clinical-stage biotechnology company developing precision genetic medicines using base editing — a gene-editing approach that alters individual DNA letters without cutting the DNA double helix. With a market capitalisation around $3.02 billion, Beam is primarily research and development-driven: value depends heavily on clinical trial readouts, regulatory reviews and the commercial potential of a still-early pipeline. The company has collaborations and licensing arrangements typical of the sector and relies on capital markets or partners to fund development. Investors should be aware that biotech equities can be volatile and subject to binary outcomes from trial results; revenue is limited while R&D and clinical costs remain high. This makes Beam a higher-risk, potentially higher-reward holding suitable for investors comfortable with long horizons and concentrated biotech exposure. This is educational information, not personalised advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Beam Therapeutics stock, expecting it to rise significantly in value.
Financial Health
Beam Therapeutics is generating solid revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BEAM
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: June 17, 2025
Explore BasketDeep Future
This collection features companies pioneering revolutionary technologies that could transform our world in the decades ahead. Carefully selected by our analysts, these stocks represent visionary enterprises working on quantum computing, next-generation energy, and genetic medicine breakthroughs.
Published: June 17, 2025
Explore BasketSolar Eclipse Black Box
This carefully selected group of stocks represents breakthrough technologies developing in the shadows before their dramatic market emergence. Our professional analysts have identified companies pioneering quantum computing, gene editing, and other innovations with potential for explosive growth once they step into the spotlight.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision gene editing
Beam’s base-editing platform aims for targeted DNA changes that could address genetic diseases, though clinical proof of concept remains essential and uncertain.
Clinical catalysts ahead
Upcoming trial readouts and regulatory updates can materially affect valuation, making timing and binary outcomes important for investors to monitor.
Long-term potential
If successful, therapies may address unmet needs and create durable value, but development is costly and outcomes are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
